Background and objectives: The aim of this study was to research oxidative stress and thiol/disulphide homeostasis in Graves’ patients. Materials and Methods: The study included 33 Graves’ patients (research group) and 35 healthy subjects (control group). Serum oxidative stress and thiol/disulphide homeostasis (a new and automated spectrophotometric method developed by Erel and Neselioglu) parameters were studied and compared between the groups. Results: The native and total thiol levels and the native thiol/total thiol ratio were lower in patients with Graves’ disease compared to the control group (p < 0.001, p < 0.001, and p = 0.006, respectively). TOS (total antioxidant status), PC (protein carbonyl), OSI (Oxidative stress index), and disulphide/native thiol and disulphide/total thiol ratios were determined to be higher in the Graves’ disease group than in the control group (p < 0.001, p = 0.001, p = 0.001, p = 0.004, and p = 0.006, respectively). In the Graves’ disease group, the free triiodothyronine (FT3) and free thyroxine (FT4) levels were significantly positively correlated with impaired thiol/disulphide homeostasis and oxidative stress parameters (p < 0.05). Conclusion: The results of the current study demonstrated that oxidative stress and thiol/disulphide homeostasis increased towards disulphide formation due to thiol oxidation in Graves’ disease. In addition, a positive correlation of FT3 and FT4 was observed with oxidative stress parameters and impaired thiol/disulphide homeostasis.

Background: Drug–drug interactions are undesirable, as they reduce drug bioavailability. Drug–reagent interactions in biochemical tests may directly affect the accuracy of test results. Objective: The aim of the present study was to investigate the impact of drug–reagent interactions of drugs used in cardiology on different cardiac markers (troponin I, Nt-proBNP, CK-MB mass, CK, AST, and LDH) and the D-dimer test. Method: Eleven drugs (enoxaparin, tirofiban hydrochloride monohydrate, diltiazem, glyceryl trinitrate, metoprolol, epinephrine, heparin sodium, atropine sodium, furosemide, norepinephrine tartrate, and amiodarone HCl) were tested in an interference study. The interference protocol was applied to the control material of troponin I, CK-MB mass, Nt-proBNP, CK, AST, LDH tests with 11 different drugs and performed with analyzers. Cardiac Markers Plus Control (Bio-Rad, Irvine, CA, USA; Lot: 23662) materials were used to assess the impact of drug–reagent interactions on the accuracy of tests of cardiac markers based on immunoassay methods. The bias rate, defined as the extent of deviation from the target value (bias %), in the interference study was calculated in each test. Results: For all 11 drugs, positive interference in the range of 43.58% to 130.06% occurred in the CK-MB mass test, whereas positive interference in the range of 11.98% to 107.44% occurred in the troponin I test. All the drugs, except enoxaparin sodium, led to negative interference in the range of -84.21 to -29.6% in the Nt-proBNP test. In the D-dimer test, amiodarone HCl and diltiazem caused interference (122.87% and 28.08%, respectively). The percentage of interference caused by the other drugs ranged from -1.27% to 11.44%. Minimal deviations the target values (between -3.31% and 3.86%) were observed in the CK, AST, and LDH tests measured using spectrophotometric methods. Conclusion: Parenteral drugs used in cardiology can significantly interfere with troponin I, CK-MB mass, Nt-proBNP, and D-dimer tests in the analytical phase because of drug–reagent interactions. Minimal deviations in the CK, AST, and LDH tests were observed using spectrophotometric methods. Thus, changes in test results may be due to drug interference rather than the treatment itself. Clinicians should consider the possibility of drug interference in cases of doubtful cardiac test results that do not comply with the diagnosis.

This study investigated the antioxidant and anticancer properties, phenolic compounds, and content profile of Hypericum salsolifolium plant extracts prepared with different solvents. The total phenolic content, total flavonoid content, and antioxidant potential [(2,2-diphenyl-1-picrylhydrazyl, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), ferric reducing antioxidant power, and cupric reducing antioxidant capacity assays] of Hypericum salsolifolium extracts obtained using solvents of different polarities (hexane, dichloromethane, methanol, and water) were measured using spectrophotometric methods. The contents of the extracts were analyzed using liquid chromatography–mass spectrometry and inductively coupled plasma—mass spectrometry methods. Anticancer detection was performed in human lung carcinoma cells using the 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide, annexin-V, and cell cycle assays, as well as fluorescence detection of acridine orange/ethidium bromide staining. The methanolic extract was determined to have higher activation values of total phenolics, total flavonoids, ferric reducing antioxidant power, and in the 2,2-diphenyl-1-picrylhydrazyl assay than the other extracts, and the aqueous extract had higher values in the 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) and cupric reducing antioxidant capacity assays. The methanolic extract showed a cytotoxic effect against human lung carcinoma cells (IC50: 141.96 µg/mL). It was found that Hypericum salsolifolium extract showed antioxidant and anticancer activities. It was concluded that this plant can be used as a nutritional supplement due to its glucose, phenolic compound, amino acid, and vitamin content.